A phase 2, Randomized, double-blind, Placebo-Controlled study to evaluate the effect of Add-on AMG 747 on schizophrenia negative symptoms- Pharmacokinetic sub study [SUBSTUDY OF 700215758]

Trial Profile

A phase 2, Randomized, double-blind, Placebo-Controlled study to evaluate the effect of Add-on AMG 747 on schizophrenia negative symptoms- Pharmacokinetic sub study [SUBSTUDY OF 700215758]

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Tilapertin (Primary) ; Antipsychotics
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Jun 2013 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 18 Apr 2013 Planned number of patients changed from 50 to 90 as reported by UKCRN.
    • 15 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top